VestGen Advisors’s Invesco Biotechnology & Genome ETF PBE Stock Holding History

VestGen Advisors’s Portfolio PBE Stock Details PBE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$220K	Sell	2,459 -2	-0.1%	-$165	0.01%	992
2026 Q1	$204K	Sell	2,461 -149	-6%	-$12K	0.01%	998
2025 Q4	$214K	Sell	2,610 -2,074	-44%	-$160K	0.01%	708
2025 Q3	$327K	Sell	4,684 -20	-0.4%	-$1.35K	0.01%	579
2025 Q2	$313K	Sell	4,704 -346	-7%	-$21.4K	0.01%	499
2025 Q1	$320K	Buy	+5,050	New	+$340K	0.01%	448

Other funds holding PBE

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UCFA

United Capital Financial Advisors Irving, Texas $18.2B AUM 22.02% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

GKWIM

Gerber Kawasaki Wealth & Investment Management Santa Monica, California $3.75B AUM 28.61% 1-Year Est. Return

Cetera Investment Advisers Schaumburg, Illinois $110B AUM 26.29% 1-Year Est. Return

YIA

YHB Investment Advisors West Hartford, Connecticut $1.56B AUM 27.39% 1-Year Est. Return

VestGen Advisors's PBE Position: Q2 2026 in Review

VestGen Advisors reduced its Invesco Biotechnology & Genome ETF (PBE) stake by 0.08% in Q2 2026, selling an estimated $165 and leaving 2,459 shares worth $220K. The position accounts for 0.01% of the portfolio, ranked #992.

VestGen Advisors first reported a position in PBE in Q1 2025 and has held it in 6 quarters since. The position peaked at $327K in Q3 2025. 105 funds tracked by Wall St. Rank hold PBE as of Q2 2026.

VestGen Advisors held 2,459 shares of Invesco Biotechnology & Genome ETF worth $220K as of Q2 2026.
VestGen Advisors sold 2 Invesco Biotechnology & Genome ETF shares in Q2 2026, an estimated $165.
Invesco Biotechnology & Genome ETF made up 0.01% of VestGen Advisors's portfolio in Q2 2026, its #992 holding.
VestGen Advisors first reported a position in Invesco Biotechnology & Genome ETF in Q1 2025 and has held it in 6 quarters since.
VestGen Advisors's Invesco Biotechnology & Genome ETF position peaked at $327K in Q3 2025.
105 funds tracked by Wall St. Rank held Invesco Biotechnology & Genome ETF as of Q2 2026.

Based on VestGen Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.